Ramzi M Mohammad
Overview
Explore the profile of Ramzi M Mohammad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bannoura S, Aboukameel A, Khan H, Uddin M, Jang H, Beal E, et al.
Cancer Lett
. 2024 Sep;
604:217275.
PMID: 39321913
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with limited therapeutic options. Here, we evaluated the role of regulator of chromosome condensation 1 (RCC1) in PDAC. RCC1 functions as...
2.
Bannoura S, Khan H, Uddin M, Mohammad R, Pasche B, Azmi A
Expert Opin Drug Discov
. 2024 Jun;
19(8):949-959.
PMID: 38884380
Introduction: Guanine nucleotide exchange factors (GEFs) regulate the activation of small GTPases (G proteins) of the Ras superfamily proteins controlling cellular functions. Ras superfamily proteins act as 'molecular switches' that...
3.
Uddin M, Al-Hallak M, Khan H, Aboukameel A, Li Y, Bannoura S, et al.
Clin Transl Med
. 2023 Dec;
13(12):e1513.
PMID: 38131168
Background: The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin-bound (nab)-paclitaxel (GemPac) necessitating the need for a more effective treatment...
4.
Khan H, Nagasaka M, Aboukameel A, Alkhalili O, Uddin M, Bannoura S, et al.
Mol Cancer Ther
. 2023 Sep;
22(12):1422-1433.
PMID: 37703579
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug resistance. To address this...
5.
Khan H, Nagasaka M, Aboukameel A, Alkhalili O, Uddin M, Bannoura S, et al.
bioRxiv
. 2023 Apr;
PMID: 37034616
Significance: KRASG12C inhibitors demonstrate limited durable response in patients with KRASG12C mutations. In this study, combining PAK4 inhibitor KPT9274 with KRASG12C inhibitors has resulted in potent antitumor effects in preclinical...
6.
Uddin M, Mohammad R, Philip P, Azmi A, Muqbil I
Am J Physiol Cell Physiol
. 2022 Oct;
323(6):C1624-C1632.
PMID: 36280389
Cachexia is an acute syndrome that is very commonly observed in patients with cancer. Cachexia is the number one cause of death in patients with metastatic disease and is also...
7.
Li Y, Azmi A, Mohammad R
Semin Cancer Biol
. 2022 Aug;
86(Pt 3):122-134.
PMID: 35940398
Transcription factors are a group of proteins, which possess DNA-binding domains, bind to DNA strands of promoters or enhancers, and initiate transcription of genes with cooperation of RNA polymerase and...
8.
Khan H, Nagasaka M, Li Y, Aboukameel A, Uddin M, Sexton R, et al.
Cancer Res Commun
. 2022 May;
2(5):342-352.
PMID: 35573474
Significance: In this study, combining nuclear transport inhibitor selinexor with KRAS G12C inhibitors has resulted in potent antitumor effects in preclinical cancer models. This can be an effective combination therapy...
9.
Khan H, Uddin M, Balasubramanian S, Sulaiman N, Iqbal M, Chaker M, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008323
Diffuse large B-cell lymphoma (DLBCL), grade 3b follicular lymphoma (FL), and mantle cell lymphoma (MCL) are aggressive non-Hodgkin's lymphomas (NHL). Cure rates are suboptimal and novel treatment strategies are needed...
10.
Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs
Li Y, Al Hallak M, Philip P, Azmi A, Mohammad R
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439315
Pancreatic cancer is an aggressive malignance with high mortality. The lack of early diagnosis and effective therapy contributes to the high mortality of this deadly disease. For a long time...